Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research342

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research342

FiltersClear all

Status

Recruiting2
Active, not recruiting50
Completed203
Terminated87

Study type

Interventional342
Observational5

Phase

Phase 2113
Phase 3108
Not applicable50
Phase 423
Phase 1/219
Phase 115

Investigator

Manish A Shah11
Gail J Roboz10
Sonal Kumar10
Cora Sternberg8
Marshall J. Glesby8

Show all 50

Department

Medicine243
Pediatrics21
Obstetrics and Gynecology11
Neurology10
Dermatology9

Show all 17

Condition

COVID-1917
Prostatic Neoplasms17
Leukemia, Myeloid, Acute12
HIV Infections11
Neoplasms11

Intervention type

Drug265
Biological41
Device39
Other38
Procedure20
Behavioral14

Sponsor type

Industry209
WCM (investigator-initiated)53
Other academic44
NIH28
Cooperative group8

Start date

Has results posted342

Interventional×Has results posted×Clear all

Showing 1–20 of 342 studiesSort:

Active, not recruitingInterventional · Phase 2NCT02365597 ↗
A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations

FiltersClear all

Status

Recruiting2
Active, not recruiting50
Completed203
Terminated87

Study type

Interventional342
Observational5

Phase

Phase 2113
Phase 3108
Not applicable50
Phase 423
Phase 1/219
Phase 115

Investigator

Manish A Shah11
Gail J Roboz10
Sonal Kumar10
Cora Sternberg8
Marshall J. Glesby8

Show all 50

Department

Medicine243
Pediatrics21
Obstetrics and Gynecology11
Neurology10
Dermatology9

Show all 17

Condition

COVID-1917
Prostatic Neoplasms17
Leukemia, Myeloid, Acute12
HIV Infections11
Neoplasms11

Intervention type

Drug265
Biological41
Device39
Other38
Procedure20
Behavioral14

Sponsor type

Industry209
WCM (investigator-initiated)53
Other academic44
NIH28
Cooperative group8

Start date

Has results posted342

Interventional×Has results posted×Clear all

Showing 1–20 of 342 studiesSort:

Active, not recruitingInterventional · Phase 2NCT02365597 ↗
A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations

Phase 2/3

Show fewer

Ellen K. Ritchie8
Ashish Saxena7
Catherine Butkus Small7
Matthew William McCarthy7
Scott T. Tagawa7
Catherine McGuinn6
Daniel W Skupski6
James E. Ip6
Kristen Marks6
Pinkal Desai6
Robert J. Kaner6
Harini Sarva5
Evelyn M. Horn5
Randy Longman5
Ruben Niesvizky5
Aliza B Solomon4
Doru Paul4
Ellen J Scherl4
Hani Lamie Ashamalla4
Joseph M Scandura4
John Allan4
Jia Ruan4
Jean W. Pape4
Parag Goyal4
Sujit Sheth4
Alexander Drelick3
Andrew F. Alexis3
Christopher F Liu3
Georgiana Alina Dobri3
Holly G Prigerson3
Jim W. Cheung3
Louis J Aronne3
Lok W. Yung3
Maria Teresa DeSancho3
Robert S. Brown3
Sebastian A. Mayer3
Shari Lipner3
Tsiporah B Shore3
Timothy Wilkin3
Andrea Heras2
Anna Podolanczuk2
Alpana P. Shukla2
Barbara Ma2
David Fishman2
Darshana M Dadhania2

Show fewer

Radiology9
Radiation Oncology8
Urology8
Psychiatry6
Surgery6
Neurological Surgery4
Rehabilitation Medicine3
Cardiothoracic Surgery2
Anesthesiology1
Ophthalmology1
Pathology and Laboratory Medicine1
Population Health Sciences1

Show all 50

Show fewer

Myelodysplastic Syndromes10
Carcinoma, Non-Small-Cell Lung8
Colitis, Ulcerative7
Neoplasm Metastasis7
Recurrence7
Atrial Fibrillation6
Crohn Disease6
Heart Failure6
Hemophilia A6
Idiopathic Pulmonary Fibrosis6
Leukemia, Myelomonocytic, Chronic6
Multiple Myeloma6
Obesity6
Breast Neoplasms5
Coronavirus Infections5
Hypertension5
Non-alcoholic Fatty Liver Disease5
Overweight5
Carcinoma, Transitional Cell4
Hematologic Neoplasms4
Leukemia4
Leukemia, Lymphocytic, Chronic, B-Cell4
Lung Diseases, Interstitial4
Lung Neoplasms4
Parkinson Disease4
Parkinson Disease 4, Autosomal Dominant Lewy Body4
Primary Myelofibrosis4
Tuberculosis4
Anemia3
Aortic Valve Stenosis3
Bradycardia3
Brain Neoplasms3
Depression3
Dermatitis, Atopic3
Heart Diseases3
Hematologic Diseases3
Hemorrhage3
Hepatitis C3
Hypertension, Pulmonary3
Liver Cirrhosis, Biliary3
Melanoma3
Myeloproliferative Disorders3
Nail Diseases3
Prediabetic State3
Pulmonary Arterial Hypertension3

Intervention: Drug: Erdafitinib · Drug: Midazolam · Drug: Metformin
Dates: Apr 2015 – Sep 2022· Results posted
Sponsor: Janssen Research & Development, LLC

Urothelial Cancer

Active, not recruitingInterventional · Phase 2/3NCT02598661 ↗

A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Pinkal DesaiPI

Intervention: Drug: Imetelstat Sodium · Drug: Placebo
Dates: Jan 2016 – Oct 2023· Results posted
Sponsor: Geron Corporation

Myelodysplastic Syndromes

Active, not recruitingInterventional · Phase 1/2NCT02773030 ↗

Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Ruben NiesvizkyPI

Intervention: Drug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab - 16mg/kg · Drug: Bortezomib (BTZ) · Drug: Daratumumab- 1800mg
Dates: Oct 2016 – May 2024· Results posted
Sponsor: Celgene Corporation

Multiple Myeloma

Active, not recruitingInterventional · Phase 2NCT03371719 ↗

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)

Hani Lamie AshamallaPI

Intervention: Drug: Apalutamide · Radiation: External Beam Radiation Therapy · Other: Placebo Administration
Dates: Jun 2018 – Mar 2025· Results posted
Sponsor: NRG Oncology

Recurrent Prostate CarcinomaStage III Prostate Adenocarcinoma AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7

Active, not recruitingInterventional · Phase 2/3NCT03466411 ↗

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Ellen J ScherlPI

Intervention: Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2 · Drug: Guselkumab Dose 3 · Drug: Guselkumab Dose 4 · Drug: Guselkumab Dose 5 · Drug: Guselkumab · Drug: Ustekinumab · Drug: Placebo
Dates: Apr 2018 – Oct 2023· Results posted
Sponsor: Janssen Research & Development, LLC

Crohn's Disease

Active, not recruitingInterventional · Phase 2NCT03600701 ↗

A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

Ashish SaxenaPI

Intervention: Drug: Atezolizumab · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Cobimetinib · Procedure: Computed Tomography · Procedure: Magnetic Resonance Imaging
Dates: Nov 2018 – Jul 2025· Results posted
Sponsor: National Cancer Institute

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell Carcinoma+1 more

Active, not recruitingInterventional · Phase 3NCT03602859 ↗

A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Eloise ChapmanPI

Intervention: Drug: Niraparib · Drug: Dostarlimab (TSR-042) · Drug: Standard of care · Drug: Dostarlimab-Placebo · Drug: Niraparib-Placebo
Dates: Oct 2018 – Oct 2024· Results posted
Sponsor: Tesaro, Inc.

Ovarian NeoplasmsOvarian, Fallopian Tube and Primary Peritoneal Carcinoma

Active, not recruitingInterventional · Phase 3NCT03653507 ↗

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Manish A ShahPI

Intervention: Drug: zolbetuximab · Drug: oxaliplatin · Drug: capecitabine · Drug: placebo
Dates: Nov 2018 – Oct 2022· Results posted
Sponsor: Astellas Pharma Global Development, Inc.

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more

Active, not recruitingInterventional · Phase 2/3NCT03701308 ↗

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Gail J RobozPI

Intervention: Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration · Procedure: Bone Marrow Biopsy · Drug: Cytarabine · Drug: Daunorubicin · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Drug: Uproleselan
Dates: Mar 2019 – Oct 2024· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

Acute Myeloid Leukemia

Active, not recruitingInterventional · Phase 2NCT03712202 ↗

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

Jia RuanPI

Intervention: Drug: Bleomycin · Drug: Brentuximab Vedotin · Drug: Dacarbazine · Drug: Doxorubicin · Biological: Nivolumab · Other: Quality-of-Life Assessment · Drug: Vinblastine
Dates: Nov 2018 – Nov 2024· Results posted
Sponsor: City of Hope National Medical Center

Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage I Mixed Cellularity Classic Hodgkin LymphomaAnn Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma+11 more

Active, not recruitingInterventional · Phase 2NCT03722407 ↗

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

Gail J RobozPI

Intervention: Drug: Ruxolitinib
Dates: Aug 2019 – Sep 2022· Results posted
Sponsor: H. Lee Moffitt Cancer Center & Research Institute

Chronic Myelomonocytic LeukemiaLeukemia

Active, not recruitingInterventional · Phase 2NCT03725761 ↗

A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy

Scott T. TagawaPI

Intervention: Drug: Sacituzumab Govitecan
Dates: Oct 2018 – Apr 2024· Results posted
Sponsor: University of Wisconsin

Prostate Cancer

Active, not recruitingInterventional · Phase 3NCT03737981 ↗

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)

John AllanPI

Intervention: Drug: Ibrutinib · Biological: Obinutuzumab · Other: Observation Activity · Drug: Venetoclax
Dates: Jan 2019 – Jan 2025· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Active, not recruitingInterventional · Phase 3NCT03765918 ↗

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Doru PaulPI

Intervention: Biological: Pembrolizumab 200 mg · Radiation: Radiotherapy 60 Gray · Radiation: Radiotherapy 66 Gray · Radiation: Radiotherapy 70 Gray · Drug: Cisplatin 100 mg/m^2
Dates: Dec 2018 – Jul 2024· Results posted
Sponsor: Merck Sharp & Dohme Corp

Head and Neck Neoplasms

Active, not recruitingInterventional · Phase 3NCT03907488 ↗

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Jia RuanPI

Intervention: Procedure: Biospecimen Collection · Drug: Brentuximab Vedotin · Procedure: Computed Tomography · Drug: Dacarbazine · Drug: Doxorubicin Hydrochloride · Biological: Filgrastim · Procedure: Magnetic Resonance Imaging · Biological: Nivolumab · Biological: Pegfilgrastim · Procedure: Positron Emission Tomography · Other: Quality-of-Life Assessment · Other: Questionnaire Administration · Radiation: Radiation Therapy · Drug: Vinblastine Sulfate
Dates: Aug 2019 – Mar 2024· Results posted
Sponsor: Southwest Oncology Group

Ann Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Lymphocyte-Depleted Classic Hodgkin LymphomaAnn Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma+7 more

Active, not recruitingInterventional · Phase 3NCT03914612 ↗

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Evelyn CantilloPI

Intervention: Drug: Carboplatin · Procedure: Computed Tomography · Drug: Paclitaxel · Biological: Pembrolizumab · Other: Placebo Administration · Other: Quality-of-Life Assessment · Other: Questionnaire Administration
Dates: Aug 2019 – Dec 2022· Results posted
Sponsor: NRG Oncology

Endometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid Adenocarcinoma+13 more

Active, not recruitingInterventional · Phase 2NCT03964727 ↗

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Ashish SaxenaPI

Intervention: Drug: Sacituzumab Govitecan-hziy
Dates: Oct 2019 – Jan 2025· Results posted
Sponsor: Gilead Sciences, Inc.

Metastatic Solid Tumor

Active, not recruitingInterventional · Phase 2NCT03994796 ↗

Genomically-Guided Treatment Trial in Brain Metastases

Rajiv S. MaggePI

Intervention: Drug: Abemaciclib · Drug: PI3K Inhibitor paxalisib · Drug: Entrectinib · Drug: Adagrasib
Dates: Oct 2019 – Nov 2025· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

CDK Gene MutationMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm+4 more

Active, not recruitingInterventional · Phase 2NCT04021108 ↗

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Manish A ShahPI

Intervention: Drug: Nivolumab 240 MG
Dates: Jul 2019 – Jun 2025· Results posted
Sponsor: Weill Medical College of Cornell University

Gastroesophageal Adenocarcinoma

Active, not recruitingInterventional · Not applicableNCT04089059 ↗

A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients (PROACTIVE- HF Trial)

Reema BhattPI

Intervention: Device: Cordella™ Pulmonary Artery Sensor System
Dates: Jan 2020 – Apr 2028 (est.)· Results posted
Sponsor: Endotronix, Inc.

Heart Failure NYHA Class III

‹ Prev1 2 3 4 5…14 15 16 17 18 Next ›